1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6396D21A61B394DC68525828A006B8AEB
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medical-affairs-creates-value-relationships-with-external-groups-government-agencies
18
19
203.95.23.35
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Affairs Excellence

How Medical Affairs Creates Value & Relationships with External Groups: Government Agencies and ACOs/IDNs/HCPs

ID: 5509


Features:

10 Info Graphics

19 Data Graphics

300 Metrics


Pages/Slides: 36


Published: 2018


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "How Medical Affairs Creates Value & Relationships with External Groups: Government Agencies and ACO/IDN/HCPs"

STUDY OVERVIEW


For the past decade, the external stakeholder groups that Medical Affairs groups interact with has been expanding. As a result, Medical Affairs leaders are continually adjusting roles and activities in order to effectively interact with the external groups they work with. And as government agencies and private health networks have become major players in the critical access and reimbursement arena, Medical Affairs is now sometimes providing medical support for interactions with government agencies and ACOs/IDNs/HCPs.


But with these two large groups being relatively new for Medical Affairs, pharma organizations are still working out which functions and activities resonate best with government agencies and managed care organizations. Best Practices, LLC performed this research study to probe Medical Affairs' roles, tools, effectiveness and success metrics in serving these groups.

This study will help Medical Affairs leaders identify the tools, activities, services that peers are utilizing to interact with government agencies and ACOs/IDNs/HCPs. It also provides key performance indicators and best practices to demonstrate value to these organizations.


KEY TOPICS


  • Executive Summary
  • Medical Affairs Interactions with External Groups
  • Specialized Tools, Roles, Services and Involvement Timeline with government agencies and ACO/IDN/HCPs
  • Changing Policies, Activities and KPIs of Medical Affairs to Work with government agencies and ACO/IDN/HCPs

SAMPLE KEY METRICS

  • What external groups does your Medical Affairs organization work with
  • How important are these external groups to your Medical Affairs organization
  • How effective is your Medical Affairs organization's work with these external groups
  • Which functions within your Medical Affairs organization have a role with government agencies?
  • What tools does your Medical Affairs organization use to showcase value to government agencies?
  • Rate the effectiveness of these tools used with government agencies
  • What are your key performance indicators for working with government agencies
  • What activities does your Medical Affairs organization conduct with government agencies?
  • Which functions within your Medical Affairs organization have a role with ACO/IDN/HCPs?
  • What tools does your Medical Affairs organization use to showcase value to ACO/IDN/HCPs?
  • Rate the effectiveness of these tools used with ACO/IDN/HCPs
  • What are your key performance indicators for working with ACO/IDN/HCPs
  • What activities does your Medical Affairs organization conduct with ACO/IDN/HCPs?

SAMPLE KEY FINDING

  • 63% of respondents work with government agencies, 71% of those rated their work with Govt. agencies very important but only 39% said their work was very effective.
  • 51% of respondents work with ACOs/IDNs/HCPs, 60% of those rated their work very important but only 32% viewed their work very effective. Only 15% of participants in USA consider their work with ACOs/IDNs/HCPs very effective

METHODOLOGY


For this research, Best Practices, LLC engaged 50 Medical Affairs experts at 33 companies through a benchmarking survey. Research participants include Chief Medical Officer (CMO), VPs, Heads, Directors, Managers/Leaders and Specialists.


Industries Profiled:
Biotech; Chemical; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Communications


Companies Profiled:
Genentech; Boehringer Ingelheim; Novartis; EMD Serono; Bayer; Roche; Amgen; Novo Nordisk; Astellas; Shire; Abbott; Pfizer; Sanofi; Sandoz; Takeda Pharmaceuticals; Santen; Vifor Pharma; cipla; Siemens Healthcare; UCB Pharma; Roche Diagnostics; Teva Pharmaceutical Industries Ltd; Sanofi Genzyme; Jazz Pharmaceuticals; Janssen; Ferring Pharmaceuticals; Upsher-Smith; Seattle Genetics; Otonomy; CSL Behring; Sunovion; Tillotts Pharma; ApotheCom


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.